Back to Journals » International Journal of Nanomedicine » Volume 13

Technetium-99m chelator-free radiolabeling of specific glutamine tumor imaging nanoprobe: in vitro and in vivo evaluations

Authors Ghoreishi SM, Khalaj A, Sabzevari O, Badrzadeh L, Mohammadzadeh P, Mousavi Motlagh SS, Bitarafan-Rajabi A, Shafiee Ardestani M

Received 18 November 2017

Accepted for publication 12 June 2018

Published 15 August 2018 Volume 2018:13 Pages 4671—4683


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Thomas Webster

Seyedeh Masoumeh Ghoreishi,1,2 Ali Khalaj,1 Omid Sabzevari,3 Leila Badrzadeh,1 Pardis Mohammadzadeh,1,4 Seyed Shahaboddin Mousavi Motlagh,5 Ahmad Bitarafan-Rajabi,6 Mehdi Shafiee Ardestani1

1Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; 2Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran; 3Department of Toxicology and Pharmacology, Faculty of Pharmacy, Toxicology and Poisoning Research Centre, Tehran University of Medical Sciences, Tehran, Iran; 4Department of Genetics and Molecular Biology, Isfahan University of Medical Sciences, Isfahan, Iran; 5Biotechnology Department of Iranian Food and Drug Administration, Ministry of Health, Tehran, Iran; 6Echocardiography Research Center, Cardiovascular Interventional Research Center, Department of Nuclear Medicine, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran

Introduction: Nowadays, molecular imaging radiopharmaceuticals’, nanoparticles’, and/or small-molecule biomarkers’ applications are increasing rapidly worldwide. Thus, researchers focus on providing the novel, safe, and cost-effective ones.
Materials and methods: In the present experiment, technetium-99m (99mTc)-labeled PEG-citrate dendrimer-G2 conjugated with glutamine (nanoconjugate) was designed and assessed as a novel tumor imaging probe both in vitro and in vivo. Nanoconjugate was synthesized and the synthesis was confirmed by Fourier transform infrared, proton nuclear magnetic resonance, liquid chromatography-mass spectrometry, dynamic light scattering, and static light scattering techniques. The toxicity was assessed by XTT and apoptosis and necrosis methods.
Results: Radiochemical purity indicates that the anionic dendrimer has a very high potential to complex formation with 99mTc and is also very stable in the human serum in different times. Results from the imaging procedures showed potential ability of nanoconjugates to detect tumor site.
Conclusion: Suitable features of the anionic dendrimer show that it is a promising agent to improve nanoradiopharmaceuticals.

biodegradable, biocompatible, dendrimer, glutamine, chelator free, radiolabeling

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]